DOP2014000050A - Variantes del factor 21 del crecimiento de fibroblastos - Google Patents

Variantes del factor 21 del crecimiento de fibroblastos

Info

Publication number
DOP2014000050A
DOP2014000050A DO2014000050A DO2014000050A DOP2014000050A DO P2014000050 A DOP2014000050 A DO P2014000050A DO 2014000050 A DO2014000050 A DO 2014000050A DO 2014000050 A DO2014000050 A DO 2014000050A DO P2014000050 A DOP2014000050 A DO P2014000050A
Authority
DO
Dominican Republic
Prior art keywords
variants
factor
fibroblasts
growth
variations
Prior art date
Application number
DO2014000050A
Other languages
English (en)
Inventor
Radmila Micanovic
Ryan James Darling
Craig Duane Dickinson
David Albert Driver
Malgorzata Donata Gonciarz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46964112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2014000050A publication Critical patent/DOP2014000050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a variantes estables y/o farmacológicamente potentes del factor 21 de crecimiento del fibroblasto humano (FGF21), composiciones farmacéuticas que comprenden variantes del FGF21, y métodos para tratar diabetes tipo 2, obesidad, dislipidemia, o síndrome metabólico, o cualquier combinación de los mismos, usando tales variantes.
DO2014000050A 2011-10-04 2014-03-06 Variantes del factor 21 del crecimiento de fibroblastos DOP2014000050A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161542906P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
DOP2014000050A true DOP2014000050A (es) 2014-04-15

Family

ID=46964112

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000050A DOP2014000050A (es) 2011-10-04 2014-03-06 Variantes del factor 21 del crecimiento de fibroblastos

Country Status (27)

Country Link
US (2) US8541369B2 (es)
EP (1) EP2763689B1 (es)
JP (1) JP6060167B2 (es)
KR (1) KR20140059271A (es)
CN (1) CN103906530B (es)
AP (1) AP2014007532A0 (es)
AR (1) AR087973A1 (es)
AU (1) AU2012318956A1 (es)
BR (1) BR112014007532A2 (es)
CA (1) CA2843520A1 (es)
CL (1) CL2014000801A1 (es)
CO (1) CO6910165A2 (es)
CR (1) CR20140142A (es)
DO (1) DOP2014000050A (es)
EA (1) EA201490521A1 (es)
EC (1) ECSP14013285A (es)
ES (1) ES2548214T3 (es)
IL (1) IL230754A0 (es)
IN (1) IN2014CN00782A (es)
MA (1) MA35458B1 (es)
MX (1) MX2014004159A (es)
PE (1) PE20142044A1 (es)
SG (1) SG11201401792UA (es)
TN (1) TN2014000096A1 (es)
TW (1) TWI461435B (es)
WO (1) WO2013052311A1 (es)
ZA (1) ZA201400882B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
CN104302311A (zh) * 2012-05-15 2015-01-21 伊莱利利公司 成纤维细胞生长因子21蛋白质的治疗用途
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
EP3097122B9 (en) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
PL3412302T3 (pl) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Zmodyfikowane polipeptydy fgf-21 i ich zastosowania
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN106397607A (zh) * 2016-09-13 2017-02-15 河南师范大学 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用
CN106432509B (zh) * 2016-09-13 2019-05-21 河南师范大学 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
CN106220724B (zh) * 2016-09-13 2019-10-11 河南师范大学 人成纤维细胞生长因子21重组蛋白及其制备方法和应用
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
CN111050786A (zh) 2017-09-08 2020-04-21 百时美施贵宝公司 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21)
CN110128525B (zh) * 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
JP7492463B2 (ja) * 2018-07-03 2024-05-29 ブリストル－マイヤーズ スクイブ カンパニー Ｆｇｆ－２１製剤
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US20220016211A1 (en) 2020-01-08 2022-01-20 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EA200601121A1 (ru) * 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP4809352B2 (ja) * 2004-09-02 2011-11-09 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
UY32607A (es) 2009-05-05 2010-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof

Also Published As

Publication number Publication date
SG11201401792UA (en) 2014-08-28
IN2014CN00782A (es) 2015-04-03
TN2014000096A1 (en) 2015-07-01
ECSP14013285A (es) 2014-05-31
IL230754A0 (en) 2014-03-31
CA2843520A1 (en) 2013-04-11
TW201326198A (zh) 2013-07-01
EA201490521A1 (ru) 2014-07-30
PE20142044A1 (es) 2014-12-06
MA35458B1 (fr) 2014-09-01
EP2763689A1 (en) 2014-08-13
JP2014530220A (ja) 2014-11-17
AU2012318956A1 (en) 2014-02-06
US8883726B2 (en) 2014-11-11
AR087973A1 (es) 2014-04-30
US8541369B2 (en) 2013-09-24
US20130324460A1 (en) 2013-12-05
CN103906530A (zh) 2014-07-02
CL2014000801A1 (es) 2014-09-12
KR20140059271A (ko) 2014-05-15
CR20140142A (es) 2014-05-02
EP2763689B1 (en) 2015-08-12
BR112014007532A2 (pt) 2017-04-04
CO6910165A2 (es) 2014-03-31
ZA201400882B (en) 2016-02-24
WO2013052311A1 (en) 2013-04-11
TWI461435B (zh) 2014-11-21
AP2014007532A0 (en) 2014-03-31
JP6060167B2 (ja) 2017-01-11
US20130085098A1 (en) 2013-04-04
ES2548214T3 (es) 2015-10-14
MX2014004159A (es) 2015-02-12
CN103906530B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
ECSP14013285A (es) Variantes del factor 21 del crecimiento de fibroblastos
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CR20140141A (es) Proteinas de funcion dual para el tratamiento de desordenes metabolicos
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
UY34859A (es) Análogos peptídicos de la exendina 4.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
CR20110255A (es) Nuevos compuestos 578
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY35668A (es) Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
EA201590782A1 (ru) Оксирановые амины
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
CL2011003050A1 (es) Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.